Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Orally Disintegrating Tablet Market Size During 2025–2029?
The orally disintegrating tablet market size has seen significant growth over recent years. This market is expected to expand from $14.88 billion in 2024 to $16.20 billion in 2025, achieving a compound annual growth rate (CAGR) of 8.8%. Historically, this expansion has been driven by factors such as the increasing pediatric and geriatric demographics, the rising prevalence of central nervous system disorders, the heightened demand for convenient methods of drug delivery, the growing number of dysphagia cases, and the increased adoption of outpatient care services.
The market for orally disintegrating tablets is projected to experience robust expansion over the coming years. This market is set to reach $22.53 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Several factors are expected to fuel this growth during the forecast period, including the rising incidence of chronic illnesses, a growing inclination towards self-medication, the broader adoption of telemedicine and e-pharmacies, an enhanced emphasis on personalized medicine, increased consumer demand for vegan and allergen-free formulations, and a steadily increasing elderly demographic. Key trends anticipated in the forecast period encompass the creation of multi-drug orally disintegrating tablets, their incorporation into digital health platforms, breakthroughs in packaging design to enhance stability and portability, the evolution of taste-masking technologies, and significant strides in formulation technology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25857&type=smp
What Are The Top Growth Drivers Impacting The Orally Disintegrating Tablet Market Outlook?
The rising occurrence of neurological conditions is anticipated to fuel the expansion of the orally disintegrating tablet market in the future. Neurological disorders are health issues that impact the nervous system, encompassing the brain and peripheral nerves, thereby hindering its regular operation. The growing prevalence of these disorders is primarily attributed to extended lifespans, given that ailments such as Alzheimer’s and Parkinson’s tend to occur more frequently as individuals age, resulting in a general rise in diagnoses. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker drug delivery, especially for individuals facing swallowing difficulties (dysphagia) or cognitive challenges. This boosts treatment compliance, guarantees punctual dosages, and improves the overall efficacy of therapy. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections indicating an increase to 13.8 million by 2060. Consequently, the escalating incidence of neurological disorders is driving the growth of the orally disintegrating tablet market.
How Is The Orally Disintegrating Tablet Market Segmented?
The orally disintegrating tablet market covered in this report is segmented –
1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Other PPIs
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes
What Are The Major Trends Driving The Growth Of The Orally Disintegrating Tablet Market?
Leading companies in the orally disintegrating tablet market are concentrating on innovations in drug creation, such as patient-centric drug delivery systems, to improve treatment adherence and patient outcomes. A patient-centric drug delivery system describes a method of designing and delivering medications to make them simpler and more comfortable for patients to consume, thereby enhancing their treatment experience and compliance. For example, in May 2025, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada, presenting a new therapeutic choice for treatment-resistant schizophrenia. It provides several distinctive characteristics, making it a notable contribution to the management of treatment-resistant schizophrenia in Canada. As the initial clozapine orally disintegrating tablet (ODT) available in the nation, it offers a patient-friendly alternative that dissolves swiftly in the mouth without water, assisting those who struggle with swallowing or adherence difficulties. The product is offered in multiple potencies (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling adaptable and accurate dose adjustments according to individual patient requirements. By incorporating clozapine, the only approved antipsychotic for treatment-resistant schizophrenia, this ODT formulation supports conformity with established treatment guidelines.
Which Leading Companies Dominate The Orally Disintegrating Tablet Market Share?
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, KalVista Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/orally-disintegrating-tablet-global-market-report
Which Region Is Expected To Witness The Fastest Growth In The Orally Disintegrating Tablet Market?
North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Orally Disintegrating Tablet Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25857&type=smp
Browse Through More Reports Similar to the Global Orally Disintegrating Tablet Market 2025, By The Business Research Company
Tablets Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/tablets-global-market-report
Effervescent Tablet Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/effervescent-tablet-global-market-report
Oral Solid Dosage Pharmaceutical Formulation Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model